Published in Lancet on May 09, 1987
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother (1991) 3.05
Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother (1992) 1.92
Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens. Antimicrob Agents Chemother (1990) 1.35
Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother (1993) 1.28
Evaluation of two monkey species (Macaca mulatta and Macaca fascicularis) as possible models for human Helicobacter pylori disease. J Clin Microbiol (1990) 1.27
In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother (2001) 1.06
Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori. Antimicrob Agents Chemother (1989) 1.01
Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model. Antimicrob Agents Chemother (1999) 0.82
In vitro activities of new quinolones against Helicobacter pylori. Antimicrob Agents Chemother (1997) 0.79
In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori. Antimicrob Agents Chemother (2014) 0.77
Animal model of Helicobacter pylori infection. Antimicrob Agents Chemother (1990) 0.75
Sensitivity of Campylobacter pylori to colloidal bismuth subcitrate. J Clin Pathol (1989) 0.75
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect (2012) 4.68
Specific detection of methicillin-resistant Staphylococcus species by multiplex PCR. J Clin Microbiol (1995) 4.44
A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Science (2001) 3.89
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect (2007) 3.49
Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol (1995) 3.23
Aminoglycosides: activity and resistance. Antimicrob Agents Chemother (1999) 3.11
Serogrouping of Clostridium difficile strains by slide agglutination. J Clin Microbiol (1985) 3.06
One-step purification of mouse monoclonal antibodies from ascitic fluid by DEAE Affi-Gel blue chromatography. J Immunol Methods (1982) 3.06
Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol (2000) 2.79
Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill (2013) 2.63
Acute hepatic injury associated with minocycline. Arch Intern Med (1984) 2.61
Comparison of serogrouping and polyacrylamide gel electrophoresis for typing Clostridium difficile. J Clin Microbiol (1986) 2.43
Metronidazole resistance in Helicobacter pylori. Lancet (1990) 2.21
The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis (1997) 2.14
Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother (1986) 2.12
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol (1996) 2.12
In vivo deletion of the methicillin resistance mec region from the chromosome of Staphylococcus aureus strains. J Antimicrob Chemother (2000) 1.87
Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature (1988) 1.85
Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol (1990) 1.83
Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol (1993) 1.78
Diagnosis of Helicobacter pylori infection by PCR: comparison with other invasive techniques and detection of cagA gene in gastric biopsy specimens. J Clin Microbiol (1995) 1.72
Polyclonal emergence and importation of community-acquired methicillin-resistant Staphylococcus aureus strains harbouring Panton-Valentine leucocidin genes in Belgium. J Antimicrob Chemother (2005) 1.70
Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nocardia species. J Clin Microbiol (2010) 1.69
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun (1994) 1.68
Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother (2001) 1.60
National epidemiologic surveys of Enterobacter aerogenes in Belgian hospitals from 1996 to 1998. J Clin Microbiol (2001) 1.60
Plesiomonas shigelloides septicemia in a patient with primary hemochromatosis. Clin Infect Dis (1995) 1.48
Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc Natl Acad Sci U S A (1986) 1.43
Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi-centre study using centralized facility testing. Eur J Gastroenterol Hepatol (2000) 1.41
Evaluation of a commercially available second-generation immunoglobulin G enzyme immunoassay for detection of Helicobacter pylori infection. J Clin Microbiol (1992) 1.38
Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. Arch Virol (1992) 1.37
Preliminary findings of the international typing study on Clostridium difficile. International Clostridium Difficile Study Group. Clin Infect Dis (1997) 1.37
Translational stability of native and deadenylylated rabbit globin mRNA injected into HeLa cells. Proc Natl Acad Sci U S A (1981) 1.35
Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother (2003) 1.33
Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol (1994) 1.32
Genotyping of outbreak-related and sporadic isolates of Clostridium difficile belonging to serogroup C. J Clin Microbiol (1996) 1.31
Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer (2003) 1.29
The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol (2000) 1.28
Characterization of flagella of Clostridium difficile and their role in serogrouping reactions. J Clin Microbiol (1990) 1.26
Clostridium difficile in neonates: serogrouping and epidemiology. Eur J Pediatr (1988) 1.25
Humoral antibody response to bovine leukemia virus infection in cattle and sheep. Cancer Res (1979) 1.24
Additional member of the protein-tyrosine kinase family: the src- and lck-related protooncogene c-tkl. Proc Natl Acad Sci U S A (1987) 1.24
Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol (1988) 1.24
International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol (2003) 1.23
Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother (1999) 1.23
Virulence of ten serogroups of Clostridium difficile in hamsters. J Med Microbiol (1990) 1.23
The reliability of urease tests, histology and culture in the diagnosis of Campylobacter pylori infection. Scand J Gastroenterol Suppl (1989) 1.23
Evaluation of the Xpert MRSA assay for rapid detection of methicillin-resistant Staphylococcus aureus from nares swabs of geriatric hospitalized patients and failure to detect a specific SCCmec type IV variant. Eur J Clin Microbiol Infect Dis (2010) 1.23
Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med (2001) 1.22
Validation of carbapenemase and extended-spectrum β-lactamase multiplex endpoint PCR assays according to ISO 15189. J Antimicrob Chemother (2013) 1.21
Trends in production of extended-spectrum beta-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals. J Antimicrob Chemother (2010) 1.19
Effect of antibiotics carry-over on bacterial counting by 'spiral plating'. J Antimicrob Chemother (1988) 1.19
Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (1986) 1.18
Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J Clin Microbiol (2000) 1.18
A 62-month retrospective epidemiological survey of anaerobic bacteraemia in a university hospital. Clin Microbiol Infect (2006) 1.16
Application of a technique for serogrouping Clostridium difficile in an outbreak of antibiotic-associated diarrhoea. J Infect (1986) 1.15
Bovine leukemia virus. Curr Top Microbiol Immunol (1984) 1.15
Epidemiological investigation of a nosocomial outbreak of multidrug-resistant Corynebacterium striatum at one Belgian university hospital. Clin Microbiol Infect (2013) 1.15
Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents. Eur J Epidemiol (1988) 1.12
Use of an enzyme-linked immunoassay for Clostridium difficile serogrouping. J Clin Microbiol (1993) 1.12
Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol (1987) 1.11
Isolation of Mobiluncus in four cases of extragenital infections in adult women. Eur J Clin Microbiol (1984) 1.10
Use of gas-liquid chromatography as a screening test for toxigenic Clostridium difficile in diarrhoeal stools. J Clin Pathol (1983) 1.09
Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. Vaccine (1988) 1.09
Monoclonal antibodies define eight independent antigenic regions on the bovine leukemia virus (BLV) envelope glycoprotein gp51. Virology (1982) 1.09
Substance P and nitric oxide signaling in cerebral cortex: anatomical evidence for reciprocal signaling between two classes of interneurons. J Comp Neurol (2001) 1.09
Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist (2002) 1.08
In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline. J Antimicrob Chemother (2012) 1.07
Correlation between serogroup and susceptibility to chloramphenicol, clindamycin, erythromycin, rifampicin and tetracycline among 308 isolates of Clostridium difficile. J Antimicrob Chemother (1988) 1.07
Antigenic variants of bovine leukemia virus (BLV) are defined by amino acid substitutions in the NH2 part of the envelope glycoprotein gp51. Virology (1989) 1.06
Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups. J Clin Microbiol (2001) 1.06
SAP97 concentrates at the postsynaptic density in cerebral cortex. Eur J Neurosci (2000) 1.06
Cross-reactivity of environmental bacteria with fluorescent-antibody conjugates for Legionella pneumophila. Eur J Clin Microbiol (1984) 1.06
Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993. Clin Infect Dis (1995) 1.05
Pseudomonas paucimobilis peritonitis in patients treated by peritoneal dialysis. J Clin Microbiol (1984) 1.04
Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection. Eur J Clin Microbiol Infect Dis (1992) 1.03
Biologically active epitopes of bovine leukemia virus glycoprotein gp51: their dependence on protein glycosylation and genetic variability. Virology (1984) 1.03
Eradicating Helicobacter pylori. Lancet (1992) 1.03
Detection of complement-dependent lytic antibodies in sera from bovine leukemia virus-infected animals. Ann Rech Vet (1978) 1.02
Reducing time to identification of positive blood cultures with MALDI-TOF MS analysis after a 5-h subculture. Eur J Clin Microbiol Infect Dis (2014) 1.02
Topographical analysis by monoclonal antibodies of BLV-gp51 epitopes involved in viral functions. Virology (1982) 1.02
In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem. J Antimicrob Chemother (1987) 1.01
Expression of NR2 receptor subunit in rat somatic sensory cortex: synaptic distribution and colocalization with NR1 and PSD-95. J Comp Neurol (1999) 1.01